1


Life Science Lending: Minimizing the Downside(s) to Debt

// Monica Rivera Beam, PhD - VP, Life Sciences

+ Contact
May 14, 2014
  • Email
In Part 1 and Part 2 of this series I provided examples of how debt can be used to build value and some general questions lenders may ask when putting together a proposal. A final important piece of evaluating debt, for companies and investors is the potential for debt to reduce value in the company and how can that be avoided. There are 3 major considerations to help minimize the potential downside(s) to debt: risk, overleveraging, and building a strong partnership.

Equity vs. Debt Risk

All capital is not created equal. Debt and equity are not interchangeable, and it is important to keep in mind that lenders do not benefit from the full upside potential that investors and management have, and as a result, cannot take the same downside risk. This can be seen in comparing the returns of $10 million in venture debt compared to the same amount in equity. If we assume the venture debt deal is 12 months of interest followed by 3 years of amortization with an interest rate of 10% (approximate average rate for venture debt when including banks which will typically be less than 10% and debt funds which will typically be more than 10%), the total cash return for the lender will be $2.6 million. Comparatively, the average return over the past 3 years for a VC Fund is about 2.1x, which would result in the same $10 million investment generating $11 million in cash. Keeping the difference in these returns in mind when pursuing venture debt, the VC firm should be and is rewarded for taking additional risk by receiving higher returns. Conversely, the lending partner is giving up return in exchange for a safer investment. It is important to consider this when determining if the capital need is best funded by equity, debt, or a combination of the two. High risk events or milestones should be funded by equity, not debt. For example, when the next key milestone is a binary event – the result of which will determine the success of the company (i.e. clinical trial with a single primary endpoint and no ability to look at interim data), equity should fund through the read-out of the data, and there is potential to add debt to fund the company after the positive results to provide additional runway.

Cost of Overleveraging

When deciding to go with debt an important item to think about that can sometimes be overlooked, is an understanding of how the debt will be repaid. For many life science companies, debt will be repaid not by cash flow, but by future equity rounds or partnerships. Keep the size of the next influx of capital in mind when deciding on the amount of debt to pursue. Investors, especially new investors, are providing equity to help a company grow and achieve the next milestone(s). If they see that a substantial portion of the equity round will be used to re-pay debt it can create concerns for the investor(s) and may make it more difficult to raise the round, or get the pre-money valuation expected. This is especially true when there is a bump in the road that causes a delay in achieving a milestone, or growth is slower than expected. In these cases, overleveraging of the company can make bad times worse by limiting options for the company, investors, and the lender.

Building a Strong Partnership

The most important way to avoid potential pitfalls of debt is to build a solid partnership between the company, investors, and the lender. The first step is selecting a lending partner that understands the potential risks the company will face during the term of the loan. A good understanding of the company and associated risks will enable the lender to differentiate between a delay in progress that can/will be solved given more time/capital, and an event that is a true failure for the company. The next step is to maintain open lines of communication between all parties, the more the lender knows about progress (and setbacks), the more reasonable and rational they can be when any changes to the terms of the debt facility need to be made. The quickest way to make bad times worse is to withhold information from a lender, or surprise them at the last minute with bad news that the company and investors knew was coming. If the lender feels they can’t trust the company and its investors, they will be forced to behave in a more conservative manner to ensure they protect the principal of their loan.

The views, opinions, beliefs, conclusions, and other information expressed in this material is not given, verified, or endorsed by Square 1 Financial, Inc. or any of its affiliates. Instead, this material is solely the work of the author, and represents his views, opinions, beliefs, conclusions, and other information he wishes to present, in all cases without any manner of endorsement from or verification by Square 1 Financial, Inc. or any of its affiliates. 

This material, including without limitation the statistical information herein, is provided for informational purposes only. The material is based in part upon information from third-party sources that the author believes to be reliable, but which has not been independently verified by the author, Square 1 Bank, or any Square 1 affiliate, and, as such, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal, or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to this material should be construed as a solicitation, offer, or recommendation to acquire or dispose of any investment, or to engage in any other transaction. 

All material presented, unless specifically indicated otherwise, is under copyright to the author or Square 1 Financial, Inc. (or its affiliates), and is for informational purposes only. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied, or distributed to any other party, without the prior express written permission of Square 1 Financial, Inc. or the author. All trademarks, service marks, and logos used in this material are trademarks, service marks, or registered trademarks of Square 1 Financial, Inc. or one of its affiliates. 

Square 1 Bank is a member of FDIC and Federal Reserve System. Square 1 Bank and the Square 1 logo are among the trademarks registered to Square 1 Financial, Inc. Square 1 Asset Management, a registered investment advisor, is a non-bank affiliate of Square 1 Bank. Products offered by Square 1 Asset Management are not FDIC insured, are not deposits or other obligations of Square 1 Bank, and may lose value. 

 


Back To Insights

  • Email